Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb [0.03%]
有关接受英夫利西单抗-Dyyb生物类似药的临床过程和结果
Shubha Bhat,Sarah Altajar,Divya Shankar et al.
Shubha Bhat et al.
Background: In 2016, the FDA approved infliximab-dyyb (IFX-dyyb) as a biosimilar to infliximab (IFX). Deemed to have comparable efficacy and safety to IFX, IFX-dyyb is 20%-30% less expensive, allowing significant cost sav...
One-Year Evaluation of a Targeted Medication Therapy Management Intervention for Older Adults [0.03%]
针对老年患者的用药治疗管理干预措施一年评估研究
Ashley I Martinez,Erin L Abner,Gregory A Jicha et al.
Ashley I Martinez et al.
Background: Older adults are especially susceptible to adverse effects of inappropriate medication therapy, and anticholinergic medications are common culprits for cognitive dysfunction due to their action on the central ...
Evaluating a Stone of Hope: ICER's 2019 Review of Treatments for Duchenne Muscular Dystrophy [0.03%]
筑石为希望：美国卫生证据评估与技术临床评价中心杜氏肌肉萎缩症治疗评估报告解读
John Frederick Brandsema
John Frederick Brandsema
No funding contributed to the writing of this commentary. Brandsema reports consulting for Alexion, Audentes, AveXis, Biogen, Cytokinetics, PTC Therapeutics, Sarepta, and WaVe and has received research funding as a site investigator from Al...
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment-Rationale and Empirical Support [0.03%]
关于不确定性的增量成本效益分析对价值评估的影响：理由与实证支持
Louis P Garrison Jr,Bernarda Zamora,Meng Li et al.
Louis P Garrison Jr et al.
This study received unrestricted funding from the Pharmaceutical Research Manufacturers of America. The authors also do consulting, personally or through their employment, with numerous pharmaceutical manufacturers, payers, and other stakeh...
Steven G Avey
Steven G Avey
No funding was received for the writing of this reflection. Avey is a member of the AMCP Foundation and has recently retired from MedImpact Health Systems, where he served as Vice President of Specialty Clinical Solutions.
The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy [0.03%]
德乌曼氏肌肉萎缩症的治疗：deflazacort和基因绕过疗法的有效性和价值分析
Foluso Agboola,Grace A Lin,Noemi Fluetsch et al.
Foluso Agboola et al.
Funding for this summary was contributed by Arnold Ventures, Commonwealth Fund, California Health Care Foundation, National Institute for Health Care Management (NIHCM), New England States Consortium Systems Organization, Blue Cross Blue Sh...
Effectiveness of Mobile Applications on Medication Adherence in Adults with Chronic Diseases: A Systematic Review and Meta-Analysis [0.03%]
移动应用程序改善成人慢性病患者服药依从性的效果：系统评价和 meta 分析
Yihang Peng,Han Wang,Qin Fang et al.
Yihang Peng et al.
Background: Medication adherence is frequently suboptimal in adults with chronic diseases, resulting in negative consequences. Traditional interventions to improve adherence are complex and not widely effective. Mobile ap...
Editor's Note [0.03%]
编者按
Laura E Happe
Laura E Happe
Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017 [0.03%]
前列腺药物的医保覆盖和花费（2009年至2017年）
Victoria L Bartlett,Patrick Liu,Sanket S Dhruva et al.
Victoria L Bartlett et al.
Background: Prostaglandin analogs are the most effective treatment for glaucoma, a common condition among older adults. Despite the availability of generic drugs, the costs associated with these prescription drugs are ris...
The Inclusion of Economic Endpoints as Outcomes in Clinical Trials Reported to ClinicalTrials.gov [0.03%]
临床试验注册平台ClinicalTrials.gov登记的临床试验中经济结局的报告与纳入状况
Jordan M Mitchell,Julie A Patterson
Jordan M Mitchell
Background: As medication expenditures rise, payers are increasingly demanding evidence of economic value for new medications. The 2015 Professional Society for Health Economics and Outcomes Research (ISPOR) Task Force on...